pruvanserin pruvanserin pruvanserin (emd-281,014, ly-2,422,347) is a selective 5-ht2a receptor antagonist which was under development by eli lilly and company for the treatment of insomnia. it was in phase ii clinical trials in 2008 but appears to have been discontinued as it is no longer in the company's development pipeline. in addition to its sleep-improving properties, pruvanserin has also been shown to have antidepressant, anxiolytic, and working memory-enhancing effects in animal studies. pruvanserinclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status in general: uncontrolled identifiers iupac name 7-(carbonyl)-1h-indole-3-carbonitrile cas number443144-26-1 443144-27-2 (hydrochloride)pubchem cid6433122chemspider4938310uniiul09x1d9emchemblchembl1215661comptox dashboard (epa)dtxsid40196133 chemical and physical dataformulac22h21fn4omolar mass376.435 g·mol−13d model (jsmol)interactive image smiles n#cc2c1cccc(c1c2)c(=o)n4ccn(ccc3ccc(f)cc3)cc4